Regeneron stock: buy or sell?
September 20th, 2019
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide.
Should I buy Regeneron stock?Make a decision about when to buy or sell stocks is one of the hardest parts of being a trader or investor. Trading strategies are meant for helping you in the decision process of what stocks to pick and when is the best time to buy them. At Stocks2.com, we like to use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.
None of our preferred buy setups matches with Regeneron Pharmaceuticals stock situation right now, hence this is not a suitable entry point.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Regeneron stock a buy?
Everyday, hundreds of stock ratings are published by financial analysts to indicate a particular stock's attractiveness.At Stocks2.com, we gathered 15 ratings published for REGN stock in the last month.
|Date||Analyst / Broker||Previous rating||Current rating|
|2019-8-7||Robert W. Baird||Neutral||Outperform|
|2019-8-7||Credit Suisse Group||n/a||Neutral|
|2019-8-7||BMO Capital Markets||n/a||Market Perform|
|2019-5-8||Morgan Stanley||n/a||Equal Weight|
|2019-4-17||Jefferies Financial Group||n/a||Hold|
|2019-2-7||BMO Capital Markets||n/a||Market Perform|
|2019-2-26||Piper Jaffray Companies||n/a||Overweight|
Regeneron stock analysis
Regeneron shares broke up the simple moving average line of 50 days today and closed at $295.87, boosted a 3.40%.
Regeneron shares crossed up the SMA line of 50 days today and closed at $295.87, boosted a 3.40%.
Shares of Regeneron boosted a brilliant 5.06% this week.
Since early April, when REGN stock price broke down the 40-weeks moving avarage line, it slid $-113.07 per share (-27.65%). Stocks below the 40-weeks moving average line are usually not recommended for average traders.
Regeneron stock price history
Regeneron stock went public on April 2nd, 1991 with a price of $22.001. Since then, REGN stock surged a 1,244.90%, with a yearly average of 44.50%. If you had invested $1,000 in Regeneron stock in 1991, it would worth $12,449.00 today.
1: Adjusted price after possible price splits or reverse-splits.
Regeneron stock historical price chart
REGN stock reached 52-week highs on March at $442.00, and all-time highs 2015-08-04 with a price of 605.93.
Regeneron stock price target is $397.00How much a stock will be priced tomorrow or next week is quite unpredictable However, banks and other financial institutions analysts, with the help of lots of data and algorithms do their best to predict the stock prices movement. You should not follow the analysts' REGN stock price predictions in the hope that they will be met as they may be wrong and not met. We detected 12 price forecasts for Regeneron Pharmaceuticals stock released in the last 30 days:
|Date||Analyst / Broker||Action||Previous target||Current target||Diff|
|2019-8-7||Robert W. Baird||Upgrades||n/a||$410.00||-|
|2019-8-7||Credit Suisse Group||Reiterates||$333.00||$325.00||-2.4%|
|2019-8-7||BMO Capital Markets||Lowers Target||n/a||$344.00||-|
|2019-5-8||UBS Group||Lowers Target||n/a||$440.00||-|
|2019-5-8||Morgan Stanley||Lowers Target||$420.00||$389.00||-7.4%|
|2019-4-17||Jefferies Financial Group||Lowers Target||$376.00||$343.00||-8.8%|
|2019-2-7||BMO Capital Markets||Raises Target||n/a||$412.00||-|
|2019-2-26||Piper Jaffray Companies||Raises Target||n/a||$487.00||-|
Financials and fundamental analysis
Earnings date and Earnings per ShareOn February, Regeneron Pharmaceuticals presented its financial report, posting a more than good growth for the Earnings per Share (EPS). Analyst expected $5.10 per share, but Regeneron Pharmaceuticals posted $5.92.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsCompared to 2017, last anual revenues report draw an exceptional gain of 14.28% to $6,710.80 M USD. Aligned with this, its profit margin (compared to sales) rocketed to 36.42%, that is $2,444.40 million.
|2013||$2,100 M||-||$424 M20.2%||-|
|2014||$2,820 M||34.26%||$348 M12.3%||-17.98%|
|2015||$4,104 M||45.55%||$636 M15.5%||82.74%|
|2016||$4,860 M||18.44%||$896 M18.4%||40.79%|
|2017||$5,872 M||20.82%||$1,199 M20.4%||33.83%|
|2018||$6,711 M||14.28%||$2,444 M36.4%||103.95%|
Quarterly financial resultsRegeneron posted $1,927.80 million in sales for 2018-Q4, a 15.89% up compared to previous quarter. Reported quarter income marked $820.35 million with a profit margin of 42.55%. Profit margin escalated a 6.81% compared to previous quarter when profit margin was 35.75%. When comparing turnover to same quarter last year, Regeneron Pharmaceuticals sales marked an outstanding increase and skyrocketed a 21.82%. Looking back to recent quarterly results, Regeneron Pharmaceuticals posted 3 negative quarters in a row.
|2017-Q1||$1,320 M||-||$249 M18.9%||-|
|2017-Q2||$1,470 M||11.36%||$388 M26.4%||55.76%|
|2017-Q3||$1,501 M||2.09%||$388 M25.9%||0.15%|
|2017-Q4||$1,582 M||5.45%||$174 M11.0%||-55.32%|
|2018-Q1||$1,511 M||-4.48%||$478 M31.6%||175.46%|
|2018-Q2||$1,608 M||6.39%||$551 M34.3%||15.36%|
|2018-Q3||$1,664 M||3.45%||$595 M35.7%||7.84%|
|2018-Q4||$1,928 M||15.89%||$820 M42.6%||37.95%|
Regeneron ownershipWhen you are planning to invest in a stock, it's always worth to check its ownership structure.
Regeneron Pharmaceuticals shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 24.61% of all shares.
In case of Regeneron Pharmaceuticals stock, 72.68% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for REGN stock account 0.00%, no big difference from last month.
For a better context understanding, the next table shows ownership data compared to other related companies:
|Market cap||$31.9 B||$9.4 B||$118.1 B||$43.5 B||$343.5 B|
|Total shares||108.0 M||111.2 M||599.7 M||184.5 M||2,640.0 M|
|Float shares||81.2 M||110.2 M||598.3 M||184.0 M||2,630.0 M|
|- Institutional holdings (%)||72.7%||88.2%||81.9%||93.4%||69.2%|
|- Insider holdings (%)||24.6%||10.8%||0.2%||0.5%||0.1%|
|Shares in short selling||0.0%||0.0%||0.0%||0.0%||0.0%|
|Friday, September 20th, 2019|
|Day range||$288.31 - $297.64|
|Average true range||$7.82|
|50d mov avg||$295.48|
|100d mov avg||$303.61|
|200d mov avg||$349.79|
Regeneron performanceTo better understand Regeneron Pharmaceuticals performance you must becnhmark its gains with other related stocks in same sector or industry. For Regeneron, the comparison is made against Alnylam Pharmaceuticals, Amgen, Biogen, , Novartis and .
Regeneron competitorsOne check before investing in any stock is to review a list of its competitors, in this case for Regeneron Pharmaceuticals. We chose 6 companies as Regeneron Pharmaceuticals competitors as they are in the same industry or have similar market objectives.
Latest Regeneron stock news
- Seeking AlphaRegeneron's Blockbuster New Launches And Innovative Pipeline Will Outweigh Eylea Biosimilar CompetitionJuly 15, 2019
- Seeking AlphaHow Regeneron Can Take Its Sad Song And Make It (Much) BetterMay 13, 2019
- Seeking AlphaAssessing If Regeneron Is In Value Territory After Shares TumbleMay 8, 2019
- InvestorPlaceRegeneron Pharmaceuticals Earnings: REGN Stock Drops on Q1 MissMay 7, 2019
- InvestorPlaceThis Is Why You Shouldn’t Count Regeneron Stock OutApril 22, 2019